Biovail Receives FDA Approval For Aplenzin (BVF-033) For The Treatment Of Depression | Depessed Jane

depressed, depression, moody, melancholy

Recent Posts

Prognosis After Attempted Suicide Impaired By Psychiatric Disorder
Somerset Mental Health Trust Will Support Armed Services Personnel, England
American College Of Physicians Finds No Substantial Differences Among "Second-Generation" Antidepressant Drugs
15.6% Of Hawaii’s Public High School Students Obese - 5,600 Students Attempted Suicide Within Past Year
News From Annals Of Internal Medicine, Nov. 18, 2008, Issue
CNS Response Provides Poster Review Regarding The Use Of SSRIs In Children And Adolescents
Depression Screening May Not Benefit Heart Disease Patients
New Data, New Directions In Management Of Mood And Anxiety Disorders - 8th International Forum For Mood And Anxiety Disorders Congress
Greater Risk Of Death For African-Americans With Depression And Heart Attack
Doctors Must Look After Their Health Too - British Medical Journal

Archives

Topics

A Depressed Life

Search

Overcome Depression

Hi, I'm Jane. I am 26, and I just graduated recently, and now I'm working in the IT department of a local company as a computer programmer. I was a christian once, but I slid and lost my faith. I stopped going to church about four years ago. I created DepressedJane.com just to journal my thoughts and feelings about depression and my mood sometimes, and post information about depression news and medical information as well. It's not the prettiest thing around, nor do I spent copious amounts of time editing my posts, but I just hope it'll be a information resource for any depression related information.

« Having A Baby Isn’t Blissful For All New Mothers | Main | According To Research From The University Of Navarra, Smokers Have A 41% Higher Risk Of Suffering Depression »

Biovail Receives FDA Approval For Aplenzin (BVF-033) For The Treatment Of Depression

By Depressed Jane | April 25, 2008

Biovail Corporation (NYSE: BVF) (TSX: BVF) announced that it has received Approval from the United States Food and Drug Administration (FDA) for its New Drug Application (NDA) for Aplenzin™ (formerly known as BVF-033), a once-daily formulation of bupropion hydrobromide developed by Biovail for the treatment of depression in adults.

Topics: A Depressed Life |

Comments